

Current Topics in Microbiology and Immunology

Volume 412

Series editors

Rafi Ahmed

School of Medicine, Rollins Research Center, Emory University, Room G211, 1510 Clifton Road, Atlanta, GA 30322, USA

Klaus Aktories

Medizinische Fakultät, Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Abt. I, Albert-Ludwigs-Universität Freiburg, Albertstr. 25, 79104, Freiburg, Germany

Arturo Casadevall

W. Harry Feinstone Department of Molecular Microbiology & Immunology, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Room E5132, Baltimore, MD 21205, USA

Richard W. Compans

Department of Microbiology and Immunology, Emory University, 1518 Clifton Road, CNR 5005, Atlanta, GA 30322, USA

Jorge E. Galan

Boyer Ctr. for Molecular Medicine, School of Medicine, Yale University, 295 Congress Avenue, room 343, New Haven, CT 06536-0812, USA

Adolfo Garcia-Sastre

Icahn School of Medicine at Mount Sinai, Department of Microbiology, 1468 Madison Ave., Box 1124, New York, NY 10029, USA

Tasaku Honjo

Faculty of Medicine, Department of Medical Chemistry, Kyoto University, Sakyo-ku, Yoshida, Kyoto, 606-8501, Japan

Bernard Malissen

Centre d'Immunologie de Marseille-Luminy, Parc Scientifique de Luminy, Case 906, 13288, Marseille Cedex 9, France

Klaus Palme

Institute of Biology II/Molecular Plant Physiology, Albert-Ludwigs-Universität Freiburg, 79104, Freiburg, Germany

Rino Rappuoli

GSK Vaccines, Via Fiorentina 1, Siena, 53100, Italy

Honorary editors

Michael B. A. Oldstone

Department of Immunology and Microbiology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA

Peter K. Vogt

Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, BCC-239, La Jolla, CA 92037, USA

More information about this series at <http://www.springer.com/series/82>

Georg Häcker
Editor

Biology of *Chlamydia*

Responsible series editor: Klaus Aktories

 Springer

Editor
Georg Häcker
Institute of Microbiology and Hygiene
Universitätsklinikum Freiburg
Freiburg
Germany

ISSN 0070-217X ISSN 2196-9965 (electronic)
Current Topics in Microbiology and Immunology
ISBN 978-3-319-71230-7 ISBN 978-3-319-71232-1 (eBook)
<https://doi.org/10.1007/978-3-319-71232-1>

Library of Congress Control Number: 2018932344

© Springer International Publishing AG, part of Springer Nature 2018

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Printed on acid-free paper

This Springer imprint is published by the registered company Springer
International Publishing AG part of Springer Nature
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Preface

Chlamydiae are obligate intracellular bacteria. They live in an intracellular vacuole (the inclusion) that they customise to permit delivery of nutrients and to provide protection against host cell defences. *Chlamydiae* have two developmental forms: one is infectious (the elementary body) but has little metabolism and the other one divides very actively but is not infectious (the reticulate body). Once a cell is infected, EBs differentiate to RBs; after a cycle of about two days, re-differentiated EBs are released, either by lysis of the host cell or by the active release of intact inclusions.

What seems rather complicated is a very successful strategy. The phylum *Chlamydiae* has been around for about two billion years, with the extant *Chlamydiae* in their extremely wide spectrum of bacterial species and vastly differing hosts split into separate lines around 700 million years ago. Many species of unicellular and multicellular hosts have their specialised *Chlamydia* but infection across these borders also occurs. The two species commonly found in humans are *Chlamydia pneumonia* (which is very common but causes only mild disease in most cases) and *C. trachomatis*, with a lower but still very substantial prevalence and great clinical importance, especially in causing infertility in female patients and scarring damage to the eyes.

We can categorise *chlamydial* infection biology and research into *Chlamydia* into two areas, both under intensive research. The first considers the interaction of the bacteria with the individual host cell: how does *Chlamydia* manage to set up its inclusion, which is accepted by the host cell basically like another organelle? The inclusion is embedded by the cytoskeleton, it is supplied with all the necessary nutrients, and it is able to set up an equilibrium with the host cell's innate defences; how does that work?

The second issue is about the infection of multicellular hosts like humans: what are the mechanisms on either side that determine immune recognition, immunopathology and potentially anti-infective protection? The biggest clinical problem of *C. trachomatis* infection is damage to tissue, either in the female genital tract (worldwide) or to the eye (blinding trachoma, especially in Africa). Human chlamydial infection may be very prolonged affairs; it is much under investigation

whether *Chlamydia* can be persistent in vivo, lying low within one host cell, or whether chronic infections reflect slowly propagating bacteria in vivo (or even re-infection).

Progress in all of these areas is rapid, and this book is the endeavour to present important developments and current thinking. The first four articles address questions of *chlamydial* microbiology and the bacterial interaction with the (human) host cell: the unusual cell wall of *Chlamydia*, where peptidoglycan was discovered only three years ago, is the focus of one article.

The next two chapters address questions of the early establishment of the bacteria in a host cell. The elementary body, the infectious form of *Chlamydia*, long considered an inactive particle, has in recent years been found to be a highly specialised form of *Chlamydia*, and its characteristics and abilities are discussed. The second of the two chapters will illustrate the ways how *Chlamydia* interacts with the host cytoskeleton; these interactions have been found to be crucial for uptake and establishment of the inclusion as well as for its maintenance and ultimately the release of the bacteria.

The enigma how *Chlamydia* manages to escape the host cell's defence mechanisms is the focus of the following article. Even epithelial cells—the regular host cell of *Chlamydia*—have numerous systems, such as apoptosis, autophagy, inflammasome and interferon signalling that can serve in the defence against microbial invaders. *Chlamydia* has to deal with these machineries, and that chapter discusses current views on this issue.

The genomic structure of *Chlamydia trachomatis* is at the centre of the next article. It focusses on the question how recent technological advances, in particular through whole-genome sequencing, have changed our perception of the genomic structure of the bacteria. Apart from the population structure, the appreciation of what is a successful strain and a new understanding of the relationship between strains causing distinct forms of disease has only become clear through these studies. One important underlying mechanism was found to be the unexpectedly large extent of recombination between chlamydial strains.

This surprising capacity for recombination has been one of the areas of discovery that have also informed the recent endeavours to manipulate the genome of *Chlamydia trachomatis*. For a long time, many papers on *Chlamydia* included the wistful statement that *Chlamydia* is not genetically tractable. This is no longer the case. Progress has been made, and some genetically modified bacteria have been characterised. The newly developed techniques will help us understand chlamydial virulence. However, we are still a long way off routine manipulation. The article on genetic dissection of *chlamydial* virulence provides an honest appraisal of exciting yet small advances and sketches out the way ahead.

Turning to the infection of the complex (especially human) host, three articles cover a number of questions that are highly relevant to human infection. One of the striking features of human genital infection with *Chlamydia trachomatis* is the chronic infection: unless the infection is cleared right away, as it is in some patients, the infection may be persistent with spontaneous rates of clearance of as low as

50% per year. One article in the book investigates the reasons and likely mechanisms of persistence and of the individually differential response to the infection.

As already mentioned, the clinically biggest problem of human infection with *Chlamydia trachomatis* is the damage to the infected tissue, which frequently is associated with female infertility but also with eye scarring. It is clear that this is at least in part immunopathology: both innate and adaptive immunity contribute to the damage. Current state of knowledge in this field, in particular from animal models, is summarised in the article on the immunopathogenesis of chlamydial infection.

The last chapter covers the prospect for a vaccine. With few exceptions, vaccines tend to be less than completely successful against bacteria, and past endeavours do not suggest that *Chlamydia* will be much different. Nevertheless, there has been progress: understanding correlates of protection and the development of subunit vaccines has been moving forward, and the opportunities and problems will be discussed in this chapter.

Like many other areas of science, research into *Chlamydia* has benefitted from new methods and has been fertilised by the interaction of specialists with different backgrounds. I do believe that this collection of articles, prepared by experts in the relevant fields, will be a great repository of up-to-date information in a fast developing area.

Freiburg, Germany
October 2017

Georg Häcker

Contents

Deconstructing the Chlamydial Cell Wall	1
Anna Klöckner, Henrike Bühl, Patrick Viollier and Beate Henrichfreise	
One Face of <i>Chlamydia trachomatis</i>: The Infectious Elementary Body	35
Mathilde M. Cossé, Richard D. Hayward and Agathe Subtil	
Manipulation of the Host Cell Cytoskeleton by <i>Chlamydia</i>	59
Ana T. Nogueira, Antonio T. Pedrosa and Rey A. Carabeo	
Subversion of Cell-Autonomous Host Defense by <i>Chlamydia</i> Infection	81
Annette Fischer and Thomas Rudel	
The Hidden Genomics of <i>Chlamydia trachomatis</i>	107
James Hadfield, Angèle Bénard, Daryl Domman and Nicholas Thomson	
Advances and Obstacles in the Genetic Dissection of Chlamydial Virulence	133
Julie A. Brothwell, Matthew K. Muramatsu, Guangming Zhong and David E. Nelson	
<i>Chlamydia trachomatis</i> as the Cause of Infectious Infertility: Acute, Repetitive or Persistent Long-Term Infection?	159
Larissa Schuchardt and Jan Rupp	
Immunopathogenesis of Chlamydial Infections	183
Ashlesh K. Murthy, Weidang Li and Kyle H. Ramsey	
<i>Chlamydia trachomatis</i>: Protective Adaptive Responses and Prospects for a Vaccine	217
Taylor B. Poston and Toni Darville	